Meeting
2020 Gastrointestinal Cancers Symposium
NSABP FC-10: Phase IB study of pembrolizumab in combination with premetrexed + oaliplatin in patients (pts) with chemo-refractory metastatic colorectal cancer (mCRC).
Authors
James J. Lee
NSABP Foundation, and The University of Pittsburgh School of Medicine, Pittsburgh, PA
James J. Lee , Greg Yothers , Thomas J. George , John C. Krauss , Bassam Nabih Maalouf , Hiral D. Parekh , Anuradha Krishnamurthy , Kelly R. Vehec , Norman Wolmark , Carmen Joseph Allegra , Samuel A. Jacobs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03626922
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr TPS262)
Abstract #
TPS262
Poster Bd #
M18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Combination of hSTC810 and capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A single arm, phase 1b/2, multicenter study.
First Author: Jiwon Lee
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck
Poster
2022 ASCO Annual Meeting
NSABP FC-10: A phase Ib study of pembrolizumab (pembro) in combination with pemetrexed (pem) and oxaliplatin (oxali) in patients with chemo-refractory metastatic colorectal cancer (mCRC).
First Author: John C. Krauss
Poster
2020 ASCO Virtual Scientific Program
Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).
First Author: Christian Grohé